Filtros de búsqueda

Lista de obras de Yair Herishanu

A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain

scientific article published on 26 July 2019

A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach

artículo científico publicado en 2017

Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study

artículo científico publicado en 2019

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Scientific article published on 3 February 2022

Familial chronic lymphocytic leukemia in Israel: A disproportionate distribution among Ashkenazi Jews

artículo científico publicado en 2017

Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group

artículo científico publicado en 2020

Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience

scientific article published on 12 March 2019

Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma

artículo científico publicado en 2020

Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials

artículo científico publicado en 2018

Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival

artículo científico publicado en 2017

Severe hepatitis B virus reactivation related to ibrutinib monotherapy

artículo científico publicado en 2017

The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants

artículo científico publicado en 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda